Oxford Covid-19 vaccine shows promising results
A much larger trial will now get underway
A new vaccine for Covid-19 has shown promising results in its initial trial phase.
Produced in the University of Oxford, the vaccine underwent trials on 1,077 people at five different British laboratories. The results of the trials showed that subjects developed antibodies and T-cells capable of fighting off the novel coronavirus.
Antibodies are proteins made by the immune system which protect against viruses, while T-cells are white blood cells that help identify and attack infected cells.
Subscribe from just €1 for the first month!
With any subscription you will have access to
Unlimited multi-device access to our iPad, iPhone and Android Apps
Unlimited access to our eReader library
Exclusive daily insight and opinion seven days a week
Create alerts to never miss a subject that matters to you
Get access to exclusive offers for subscribers on gifts and experiences
Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine
Tony O’Brien: Draft contract adds to bad blood between Department of Health and consultants
The newly published proposed Sláintecare consultant contract has led to yet another major row between the department and the very people on whom it relies for high-quality treatment outcomes
Multi-annual health budget mooted to tackle waiting lists
New plan by health department, HSE and NTPF aims to mitigate snowballing numbers waiting for treatment, exacerbated by pandemic
HSE procurement targets in doubt as Beaumont reports €14m non-compliant spend
January Covid surge and last month’s cyberattack mean ‘certain’ delays for HSE’s plan to implement a centralised spending framework and tackle non-compliant expenditure
Kathleen MacMahon: We may not be able to help our mothers, but we can still save our daughters
Thanks to the honesty and bravery of the women who called into Liveline to share stories of their distress during menopause, we’ve come a step closer to a place where their suffering is no longer acceptable